Clinical

 Trials

Our Clinical Trials

Alnylam is committed to developing new, innovative medicines to treat diseases with high unmet medical need. A clinical trial involves research using human volunteers (trial participants, including healthy volunteers or patients), and is intended to answer specific questions about potential new treatments for certain diseases. These studies allow us to evaluate whether these potential new treatments are safe and effective.

If you have questions about our clinical trials, please contact us:
Alnylam Clinical Trial Information Line
clinicaltrials@alnylam.com
866-330-0326 (Toll-free within the United States)
+1 617-575-7400 (International)

Visit www.clinicaltrials.gov to learn more about eligibility to participate in a study, risks and benefits of study participation, the informed consent process, questions to ask when considering whether to participate in a study, and much more information regarding clinical trials.

  • PATISIRAN (hATTR AMYLOIDOSIS)

    • Phase 3 Study
      Trial Status

      Enrolling

      Enrolling

      Evaluating the efficacy and safety of patisiran in participants with hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) with disease progression after liver transplant.

      Location(s):

      Italy, Sweden, Portugal, UK, Germany, Spain, France

      For more info:

      ClinicalTrials.gov – NCT03862807

    • Expanded Access Protocol Study
      Trial Status

      Completed

      Completed

      Providing expanded access of patisiran to adults with hATTR amyloidosis with polyneuropathy who meet Karnofsky performance status and Polyneuropathy Disability (PND) score requirements.

      Location(s):

      USA

      For more info:

      ClinicalTrials.gov – NCT02939820

    • Global Open-Label Extension (OLE) Study
      Trial Status

      Active

      Active, Not Recruiting

      Evaluating the long-term safety of patisiran in adults with hATTR amyloidosis with symptomatic polyneuropathy who participated in either the Phase 2 OLE study or the APOLLO study.

      Location(s):

      USA, Argentina, Australia, Brazil, Bulgaria, Canada, Cyprus, France, Germany, Italy, Japan, South Korea, Malaysia, Mexico, Netherlands, Portugal, Spain, Sweden, Taiwan, Turkey, UK

      For more info:

      ClinicalTrials.gov – NCT02510261

    • APOLLO – Phase 3 Study
      Trial Status

      Active

      Completed

      Evaluated the safety and efficacy of patisiran in adults with hereditary ATTR (hATTR) amyloidosis with symptomatic polyneuropathy (previously known as familial amyloidotic polyneuropathy [FAP]).

      Location(s):

      USA, Argentina, Australia, Brazil, Bulgaria, Canada, Cyprus, France, Germany, Italy, Japan, South Korea, Malaysia, Mexico, Netherlands, Portugal, Spain, Sweden, Taiwan, Turkey, UK

      For more info:

      ClinicalTrials.gov – NCT01960348

    • Phase 2 Open-Label Extension (OLE) Study
      Trial Status

      Completed

      Completed

      Evaluated the safety and efficacy of patisiran in adults with hATTR amyloidosis with symptomatic polyneuropathy who participated in the Phase 2 trial.

      Location(s):

      USA, Brazil, France, Germany, Portugal, Spain, Sweden

      For more info:

      ClinicalTrials.gov – NCT01961921

    • Phase 2 Study
      Trial Status

      Completed

      Completed

      Evaluated the safety and efficacy of patisiran in adults with hATTR amyloidosis with symptomatic polyneuropathy.

      Location(s):

      USA, Brazil, France, Germany, Portugal, Spain, Sweden

      For more info:

      ClinicalTrials.gov – NCT01617967

  • GIVOSIRAN (ACUTE HEPATIC PORPHYRIA)

    • ENVISION – Phase 3 Study
      Trial Status

      Completed

      Completed

      Evaluating the effect of givosiran (ALN-AS1) on the rate of porphyria attacks in patients with acute hepatic porphyria (AHP).

      Location(s):

      USA, Australia, Belgium, Bulgaria, Canada, Denmark, Finland, France, Germany, Italy, Japan, South Korea, Mexico, Netherlands, Poland, Spain, Sweden, Switzerland, Taiwan, UK

      For more info:

      ClinicalTrials.gov – NCT03338816

    • EXPLORE Natural History Study
      Trial Status

      Enrolling

      Enrolling

      A prospective observational study of adults with acute hepatic porphyria (AHP), including acute intermittent porphyria (AIP), variegate porphyria (VP), and hereditary coproporphyria (HCP), with recurrent attacks.

      Location(s):

      Australia, USA, Bulgaria, Czech Republic, Finland, France, Germany, Italy, Israel, Mexico, Netherlands, Norway, Poland, South Africa, South Korea, Spain, Switzerland, Taiwan, UK

      For more info:

      ClinicalTrials.gov – NCT02240784

    • Phase 2 Open-Label Extension (OLE) Study
      Trial Status

      Active

      Active, Not Recruiting

      Evaluating the long-term safety and tolerability of givosiran in adults with acute intermittent porphyria (AIP), who participated in the Phase 2 trial.

      Location(s):

      USA, Sweden, UK

      For more info:

      ClinicalTrials.gov – NCT02949830

    • Phase 1 Study
      Trial Status

      Completed

      Completed

      Evaluating the safety and tolerability of givosiran (ALN-AS1) in adults with acute intermittent porphyria (AIP).

      Location(s):

      USA, Sweden, UK

      For more info:

      ClinicalTrials.gov – NCT02452372

  • INCLISIRAN (HYPERCHOLESTEROLEMIA)

    • Phase 1 Study
      Trial Status

      Completed

      Completed

      Evaluated the safety and efficacy of inclisiran in adults with elevated low density lipoprotein cholesterol (LDL-C).

      Location(s):

      UK

      For more info:

      ClinicalTrials.gov – NCT02314442

  • LUMASIRAN (PRIMARY HYPEROXALURIA)

    • ILLUMINATE-A – Phase 3 Study
      Trial Status

      Active, Not Recruiting

      Evaluating the efficacy and safety of lumasiran in children and adults with primary hyperoxaluria type 1 (PH1).

      Location(s):

      USA, UK, France, Germany, Netherlands, Switzerland, Israel, UAE

      For more info:

      ClinicalTrials.gov – NCT03681184

    • Phase 1/2 Study
      Trial Status

      Completed

      Evaluating the safety and efficacy of lumasiran in healthy volunteers and in patients with primary hyperoxaluria type 1 (PH1).

      Location(s):

      USA, France, UK, Germany, Israel, Netherlands, Jordan

      Interested in learning more?

      Visit PH1trial.com for more about the PH1 trial.

      For more info:

      ClinicalTrials.gov – NCT02706886

    • Phase 2 Open-Label Extension (OLE) Study
      Trial Status

      Enrolling By Invitation

      Evaluating the long-term safety and tolerability of lumasiran in patients with primary hyperoxaluria type 1.

      Location(s):

      France, Germany, Netherlands, UK, Israel

      For more info:

      ClinicalTrials.gov – NCT03350451

    • ILLUMINATE-B – Phase 3 Study
      Trial Status

      Enrolling

      Evaluating the safety and efficacy of lumasiran in infants and young children with primary hyperoxaluria type 1 (PH1).

      Location(s):

      USA, UK, France, Germany, Israel

      For more info:

      ClinicalTrials.gov – NCT03905694

  • CEMDISIRAN (COMPLEMENT-MEDIATED DISEASES)

    • Phase 1/2 Study
      Trial Status

      Completed

      Completed

      Evaluated the safety and efficacy of cemdisiran in healthy volunteers and adults with paroxysmal nocturnal hemoglobinuria (PNH).

      Location(s):

      Spain, UK

      For more info:

      ClinicalTrials.gov – NCT02352493

    • Phase 2 Study
      Trial Status

      Enrolling

      Enrolling

      Evaluating the effect of cemdisiran on proteinuria in adults with immunoglobulin A nephropathy (IgAN), who excrete >1 gram (gm) of protein per day despite standard of care, which includes treatment with angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs).

      Location(s):

      USA, Canada, Spain, Sweden, UK, Singapore, France

      For more info:

      ClinicalTrials.gov – NCT03841448

  • VUTRISIRAN (ATTR AMYLOIDOSIS)

    • HELIOS-A – Phase 3 Study
      Trial Status

      Enrolling

      Enrolling

      Evaluating the efficacy and safety of vutrisiran (ALN-TTRSC02) in patients with hereditary transthyretin amyloidosis (hATTR amyloidosis).

      Location(s):

      USA, Bulgaria, France, Portugal, Malaysia, Cyprus, Germany, Japan, South Korea, Greece, Sweden

      INTERESTED IN LEARNING MORE?

      Visit HELIOSAstudy.com for more about the trial.

      For more info:

      ClinicalTrials.gov – NCT03759379

  • ALN-AAT02 (ALPHA-1 LIVER DISEASE)

    • Phase 1/2 Study
      Trial Status

      Active

      Active, Not Recruiting

      Evaluating the safety and tolerability of single or multiple doses of ALN-AAT02 in participants with ZZ type alpha-1 antitrypsin deficiency (PiZZ) and biopsy-proven alpha-1 antitrypsin (AAT) deficiency-associated liver disease.

      Location(s):

      UK

      For more info:

      ClinicalTrials.gov – NCT03767829

  • ALN-AGT (HYPERTENSION)

    • Phase 1 Study
      Trial Status

      Enrolling

      Enrolling

      Evaluating the safety and tolerability of ALN-AGT01 in patients with hypertension.

      Location(s):

      UK

      For more info:

      ClinicalTrials.gov – NCT03934307

SIGN UP FOR EMAIL UPDATES

Receive news and updates on the work at Alnylam that affects you most.

You are now leaving Alnylam.com

The following content may not be associated with Alnylam Pharmaceuticals. Links to all outside sites are provided as a reference for our visitors. Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.

Proceed to Site
 
 

You are now leaving Alnylam.com

The following content may not be associated with Alnylam Pharmaceuticals. Links to all outside sites are provided as a reference for our visitors. Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.

Proceed to Site
 
 

You are now leaving Alnylam.com

The following content may not be associated with Alnylam Pharmaceuticals. Links to all outside sites are provided as a reference for our visitors. Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.

Proceed to Site
 
 

You are now leaving Alnylam.com

The following content may not be associated with Alnylam Pharmaceuticals. Links to all outside sites are provided as a reference for our visitors. Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.

Proceed to Site
 
 

You are now leaving Alnylam.com

The following content may not be associated with Alnylam Pharmaceuticals. Links to all outside sites are provided as a reference for our visitors. Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.

Proceed to Site
 
 

You are now leaving Alnylam.com

The following content may not be associated with Alnylam Pharmaceuticals. Links to all outside sites are provided as a reference for our visitors. Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.

Proceed to Site
 
 

You are now leaving Alnylam.com

The following content may not be associated with Alnylam Pharmaceuticals. Links to all outside sites are provided as a reference for our visitors. Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.

Proceed to Site
 
 

You are now leaving Alnylam.com

The following content may not be associated with Alnylam Pharmaceuticals. Links to all outside sites are provided as a reference for our visitors. Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.

Proceed to Site
 
 

You are now leaving Alnylam.com

The following content may not be associated with Alnylam Pharmaceuticals. Links to all outside sites are provided as a reference for our visitors. Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.

Proceed to Site
 
 

You are now leaving Alnylam.com

The following content may not be associated with Alnylam Pharmaceuticals. Links to all outside sites are provided as a reference for our visitors. Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.

Proceed to Site
 
 

You are now leaving Alnylam.com

The following content may not be associated with Alnylam Pharmaceuticals. Links to all outside sites are provided as a reference for our visitors. Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.

Proceed to Site
 
 

You are now leaving Alnylam.com

The following content may not be associated with Alnylam Pharmaceuticals. Links to all outside sites are provided as a reference for our visitors. Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.

Proceed to Site
 
 

You are now leaving Alnylam.com

The following content may not be associated with Alnylam Pharmaceuticals. Links to all outside sites are provided as a reference for our visitors. Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.

Proceed to Site
 
 

You are now leaving Alnylam.com

The following content may not be associated with Alnylam Pharmaceuticals. Links to all outside sites are provided as a reference for our visitors. Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.

Proceed to Site
 
 

You are now leaving Alnylam.com

The following content may not be associated with Alnylam Pharmaceuticals. Links to all outside sites are provided as a reference for our visitors. Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.

Proceed to Site
 
 

You are now leaving Alnylam.com

The following content may not be associated with Alnylam Pharmaceuticals. Links to all outside sites are provided as a reference for our visitors. Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.

Proceed to Site
 
 

You are now leaving Alnylam.com

You are now being directed to another Alnylam website that contains information about specific treatment(s).

Proceed to Site
 
 

You are now leaving Alnylam.com

You are now being directed to another Alnylam website that contains information about specific treatment(s).

Proceed to Site

You are now leaving Alnylam.com

You are now being directed to another Alnylam website that contains information about specific treatment(s).

Proceed to Site
 
 

You are now leaving Alnylam.com

You are now being directed to another Alnylam website that contains information about specific treatment(s).

Proceed to Site